Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGTX Stock Forecast 2026-2027
$1.21
Current Price
$108.29M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGTX Price Targets
+230.6%
To High Target of $4.00
+189.3%
To Median Target of $3.50
+147.9%
To Low Target of $3.00
CGTX Price Momentum
0.0%
1 Week Change
+6.1%
1 Month Change
+303.3%
1 Year Change
-10.4%
Year-to-Date Change
-68.4%
From 52W High of $3.83
+384.0%
From 52W Low of $0.25
📊 TOP ANALYST CALLS
Did CGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cognition Therapeutics is one of their latest high-conviction picks.
Latest CGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CGTX has a bullish consensus with a median price target of $3.50 (ranging from $3.00 to $4.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.21, the median forecast implies a 189.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 230.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGTX Analyst Ratings
4
Buy
0
Hold
0
Sell
CGTX Price Target Range
Low
$3.00
Average
$3.50
High
$4.00
Current: $1.21
Latest CGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2026 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $4.00 |
| Dec 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 21, 2025 | B. Riley Securities | Buy | Reiterates | $N/A | |
| Nov 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 27, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 21, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Feb 26, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 19, 2024 | B. Riley Securities | Buy | Upgrade | $N/A | |
| Dec 19, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 19, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 27, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 6, 2024 | B. Riley Securities | Neutral | Downgrade | $N/A |
Cognition Therapeutics Inc. (CGTX) Competitors
The following stocks are similar to Cognition Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CGTX
Cognition Therapeutics
mkt cap
108.29M
Cognition Therapeutics Inc. (CGTX) Financial Data
Cognition Therapeutics Inc. has a market capitalization of $108.29M with a P/E ratio of -3.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.5%.
Valuation Metrics
Market Cap
$108.29M
Enterprise Value
$71.05M
P/E Ratio
-3.8x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+34.0%
Current Ratio
5.9x
Debt/Equity
1.9x
ROE
-68.5%
ROA
-48.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cognition Therapeutics Inc. (CGTX) Business Model
About Cognition Therapeutics Inc.
What They Do
Develops therapeutics for neurodegenerative disorders.
Business Model
Cognition Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of small molecule drugs for age-related degenerative diseases. The company generates revenue primarily through the advancement of its lead candidate, zervimesine, in clinical trials targeting conditions such as Alzheimer's disease and geographic atrophy, with the potential for future commercialization upon successful trial outcomes.
Additional Information
Founded in 2007 and based in Purchase, New York, Cognition Therapeutics is addressing significant unmet medical needs in neurodegenerative and neuro-ophthalmic diseases. The company is progressing through Phase 2 and planned Phase 3 clinical studies, which aim to assess the safety, tolerability, and efficacy of its investigational treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Ms. Lisa Ricciardi
Country
United States
IPO Year
2021
Website
www.cogrx.comCognition Therapeutics Inc. (CGTX) Latest News & Analysis
Latest News
Quick Summary
Cognition Therapeutics, Inc. (Nasdaq: CGTX) will have CEO Lisa Ricciardi present updates on DLB psychosis registration plans at two June financial conferences. Webcasts available on their website.
Why It Matters
Cognition Therapeutics' CEO is presenting updates on a key registration program, potentially influencing investor sentiment and stock performance based on the progress in treating DLB psychosis.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics held a productive meeting with the FDA regarding its registrational program for neurodegenerative disorder treatments on May 20, 2026.
Why It Matters
Positive discussions with the FDA signal potential progress for Cognition Therapeutics' drug development, which could enhance investor confidence and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics, Inc. (NASDAQ: CGTX) received a second philanthropic donation to support its expanded access program for dementia with Lewy bodies, extending treatment for two years.
Why It Matters
Cognition Therapeutics' extended EAP and new funding highlight strong support for its neurodegenerative drug development, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
1 month ago
Quick Summary
Cognition Therapeutics (NASDAQ: CGTX) plans a May 2026 meeting with the FDA regarding zervimesine for DLB psychosis, alongside reporting Q1 2026 financial results.
Why It Matters
The FDA meeting could shape zervimesine's approval path, impacting Cognition Therapeutics' stock value and market potential in treating DLB psychosis.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics' CEO, Lisa Ricciardi, will present at the Needham Virtual Healthcare Conference on April 13, providing updates on Alzheimer's and DLB drug development programs.
Why It Matters
Cognition Therapeutics' CEO presentation may lead to insights on drug development progress, influencing stock performance and investor sentiment regarding Alzheimer's and DLB treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics is advancing Zervimesine (CT1812) for dementia with Lewy bodies psychosis, with an $80 million Phase 2 trial readout expected in H2 2027.
Why It Matters
Cognition Therapeutics is advancing a promising treatment for dementia with Lewy bodies, with a fully funded trial set to yield results in 2027, indicating potential growth and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CGTX Stock
What is Cognition Therapeutics Inc.'s (CGTX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Cognition Therapeutics Inc. (CGTX) has a median price target of $3.50. The highest price target is $4.00 and the lowest is $3.00.
Is CGTX stock a good investment in 2026?
According to current analyst ratings, CGTX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGTX stock?
Wall Street analysts predict CGTX stock could reach $3.50 in the next 12 months. This represents a 189.3% increase from the current price of $1.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cognition Therapeutics Inc.'s business model?
Cognition Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of small molecule drugs for age-related degenerative diseases. The company generates revenue primarily through the advancement of its lead candidate, zervimesine, in clinical trials targeting conditions such as Alzheimer's disease and geographic atrophy, with the potential for future commercialization upon successful trial outcomes.
What is the highest forecasted price for CGTX Cognition Therapeutics Inc.?
The highest price target for CGTX is $4.00 from Daniil Gataulin at Chardan Capital, which represents a 230.6% increase from the current price of $1.21.
What is the lowest forecasted price for CGTX Cognition Therapeutics Inc.?
The lowest price target for CGTX is $3.00 from at , which represents a 147.9% increase from the current price of $1.21.
What is the overall CGTX consensus from analysts for Cognition Therapeutics Inc.?
The overall analyst consensus for CGTX is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are CGTX stock price projections?
Stock price projections, including those for Cognition Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 10:21 PM UTC